Statens Serum Institut Large Danish Study Finds No Link Between Vaccines and Autism or 49 Other Health Conditions
A new Danish study finds no association between aluminum in childhood vaccines and 50 different health conditions, including autism, asthma, and autoimmune diseases. The findings reaffirm the safety of Denmark’s childhood vaccination program.
An extensive new Danish register-based study - the largest of its kind - supports the safety of the national childhood immunization program. Analyzing data from over 1 million children, the study found no increased risk of autism, asthma, or autoimmune diseases in vaccinated children.
“Our results are reassuring. By analyzing data from more than one million Danish children, we found absolutely no indication that the very small amount of aluminum used in the childhood vaccination program increases the risk of 50 different health outcomes during childhood,” says Anders Hviid, Head of Department at Statens Serum Institut (SSI) and principal investigator on the study.
Aluminum, used as an adjuvant to enhance the immune response, has been a component in some vaccines since the 1930s.
Researchers from SSI used Denmark’s unique national health registers to follow children born between 1997 and 2018, investigating the associations between aluminum-containing vaccines and a total of 50 health outcomes - including asthma, allergies, autoimmune conditions, and neurodevelopmental disorders.
“This is the first study of this scale and with such comprehensive analyses, and it confirms the strong safety profile of the vaccines we’ve used for decades in Denmark,” says Anders Hviid.
The results are being published at a time of heightened international debate about vaccine safety which makes the Danish study highly relevant.
“In an era marked by widespread misinformation about vaccines, it is crucial to rely on solid scientific evidence. Large, population-based register studies like this one - tracking more than a million children over many years - are a bulwark against the politicization of health science which undermines public trust in vaccines. It is absolutely essential to distinguish real science from politically motivated campaigns - otherwise, it is the children who will end up paying the price,” says Anders Hviid.
Reference:
Andersson NW, Bech Svalgaard I, Hoffmann SS, et al. Aluminum-adsorbed vaccines and chronic diseases in childhood. A nationwide cohort study.Ann Intern Med. 15 July 2025. [Epub ahead of print]. doi:10.7326/ANNALS-25-00997
Fact Box:
- Researchers from Statens Serum Institut (SSI) used Denmark’s unique health registers to analyze data from more than 1 million Danish children born between 1997 and 2018 to investigate potential long-term health effects of aluminum-containing vaccines.
- The study examined 50 different conditions and found no statistical association between aluminum content in vaccines and increased risk of developing autism, autoimmune diseases, asthma, or allergic conditions such as hay fever and food allergies.
-
The study has just been published in the prestigious medical journal Annals of Internal Medicine.
Source: Statens Serum Institut (SSI)
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714416158/en/
Contacts
Anders Hviid, aii@ssi.dk
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press Release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector15.12.2025 14:03:00 CET | Press Release
Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/ Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s leading AI health management app. Positioned as an AI health companion service, AQ currently answers over 5 million health-related questions every day. The announcement comes amid China’s ongoing demographic shift. According to projections from the National Health Commission, by around 20
Copeland and Daikin Cooperation Brings Solutions to European Customers15.12.2025 14:00:00 CET | Press Release
Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industry reports as a cornerstone technology helping to reduce global carbon dioxide emissions by an estimated 500 million tons by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215625806/en/ (Left to right) Ross B. Shuster, CEO of Copeland and Jiro Tomita, executive associate officer of Daikin As Europe rapidly transitions away from fossil fuels, the demand for residential heat pumps is growing in parallel with ambitious sustainabil
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press Release
Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower cost in payments, so with the support of Visa, we are evaluating how this technology could fit into our broader strategy to deliver meaningful value to ou
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom